Cargando…

Efficacy and Safety of the Long-Acting Diquafosol Ophthalmic Solution DE-089C in Patients with Dry Eye: A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study

INTRODUCTION: DE-089C is a newly developed long-acting formulation of diquafosol ophthalmic solution with less frequent administration (three times daily) than the currently approved and clinically used diquafosol ophthalmic solution (six times daily), hereinafter referred to as DQS. DE-089C is desi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hori, Yuichi, Oka, Koji, Inai, Maya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309120/ https://www.ncbi.nlm.nih.gov/pubmed/35716319 http://dx.doi.org/10.1007/s12325-022-02194-2

Ejemplares similares

A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients
por: Takamura, Etsuko, et al.
Publicado: (2012)

Clinical utility of 3% diquafosol ophthalmic solution in the treatment of dry eyes
por: Koh, Shizuka
Publicado: (2015)

Effectiveness and Adherence of Dry Eye Patients Who Switched from Short- to Long-Acting Diquafosol Ophthalmic Solution
por: Ishikawa, Sho, et al.
Publicado: (2023)

Short-term application of diquafosol ophthalmic solution benefits children with dry eye wearing orthokeratology lens
por: Yang, Yuanfang, et al.
Publicado: (2023)

Effects of 3% diquafosol sodium ophthalmic solution on higher-order aberrations in patients diagnosed with dry eye after cataract surgery
por: Inoue, Yasushi, et al.
Publicado: (2016)

Prolonged increase in tear meniscus height by 3% diquafosol ophthalmic solution in eyes with contact lenses
por: Nagahara, Yukiko, et al.
Publicado: (2015)

Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease
por: Mun, Yongseok, et al.
Publicado: (2018)

The Combined Impact of Intense Pulsed Light Combined and 3% Diquafosol Ophthalmic Solution on Evaporative Dry Eye: A Randomized Control Study
por: Chen, Jiayan, et al.
Publicado: (2023)

Correction: The Combined Impact of Intense Pulsed Light Combined and 3% Diquafosol Ophthalmic Solution on Evaporative Dry Eye: A Randomized Control Study
por: Chen, Jiayan, et al.
Publicado: (2023)

Combination therapy with 3% diquafosol tetrasodium ophthalmic solution and sodium hyaluronate: an effective therapy for patients with dry eye after femtosecond laser-assisted in situ keratomileusis
por: Wang, Tianjiao, et al.
Publicado: (2023)

Effect of Diquafosol Ophthalmic Solution on Airflow-Induced Ocular Surface Disorder in Diabetic Rats
por: Dota, Atsuyoshi, et al.
Publicado: (2020)

Tear volume estimation using a modified Schirmer test: a randomized, multicenter, double-blind trial comparing 3% diquafosol ophthalmic solution and artificial tears in dry eye patients
por: Miyake, Hideki, et al.
Publicado: (2016)

Long-term Rebamipide and Diquafosol in Two Cases of Immune-Mediated Dry Eye
por: Yamane, Mio, et al.
Publicado: (2015)

Effect of topical 3% diquafosol sodium on eyes with dry eye disease and meibomian gland dysfunction
por: Amano, Shiro, et al.
Publicado: (2017)

Comparison of matrix metallopeptidase-9 expression following cyclosporine and diquafosol treatment in dry eye
por: So, Ha Rim, et al.
Publicado: (2023)

3% diquafosol sodium eye drops in Chinese patients with dry eye: a phase IV study
por: Wang, Wenying, et al.
Publicado: (2023)

Association between mask-associated dry eye (MADE) and corneal sensations
por: Itokawa, Takashi, et al.
Publicado: (2023)

Protocol for a parallel assignment prospective, randomised, comparative trial to evaluate the safety and efficacy of intense pulsed light (IPL) combined with 3% diquafosol (DQS) ophthalmic solution in dry eye syndrome
por: Chen, Jiayan, et al.
Publicado: (2023)

Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial
por: Park, Chang Hyun, et al.
Publicado: (2019)

Diquafosol ophthalmic solution enhances mucin expression via ERK activation in human conjunctival epithelial cells with hyperosmotic stress
por: Lee, Hyun Jung, et al.
Publicado: (2022)

Efficacy of rebamipide 2% ophthalmic solution in the treatment of dry eyes
por: Shrivastava, Saurabh, et al.
Publicado: (2018)

Long-Term Safety and Effectiveness of Diquafosol for the Treatment of Dry Eye in a Real-World Setting: A Prospective Observational Study
por: Ohashi, Yuichi, et al.
Publicado: (2019)

Prevention of Surgery-Induced Dry Eye by Diquafosol Eyedrops after Femtosecond Laser-Assisted Cataract Surgery
por: Yamazaki, Kenichiro, et al.
Publicado: (2022)

Retraction Note: Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial
por: Park, Chang Hyun, et al.
Publicado: (2020)

Two Randomized, Double-masked, Placebo-controlled Studies of the Local Anesthetic Effect of Articaine Ophthalmic Solution
por: Gonzalez, Victor H, et al.
Publicado: (2023)

Safety and efficacy of topical diquafosol for the treatment of dry eye disease: An updated meta-analysis of randomized controlled trials
por: Liu, Shuang, et al.
Publicado: (2023)

Safety and efficacy of pilocarpine, cevimeline, and diquafosol compared to artificial tears for the treatment of dry eye: protocol for a systematic review
por: Serrano-Robles, José Gerardo, et al.
Publicado: (2022)

Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease
por: de Oliveira, Rodrigo Carlos, et al.
Publicado: (2019)

Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
por: White, Darrell E, et al.
Publicado: (2019)

Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis
por: Karpecki, Paul, et al.
Publicado: (2023)

Efficacy of Topical Cyclosporine Nanoemulsion 0.05% Compared with Topical Cyclosporine Emulsion 0.05% and Diquafosol 3% in Dry Eye
por: Park, Chang Hyun, et al.
Publicado: (2019)

Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye
por: Meerovitch, Karen, et al.
Publicado: (2013)

Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study
por: Donnenfeld, Eric D., et al.
Publicado: (2016)

Influence on ocular surface after cataract surgery and effect of topical diquafosol on postoperative dry eye: a multicenter prospective randomized study
por: Miyake, Kensaku, et al.
Publicado: (2017)

Real-world assessment of diquafosol in dry eye patients with risk factors such as contact lens, meibomian gland dysfunction, and conjunctivochalasis: subgroup analysis from a prospective observational study
por: Yamaguchi, Masahiko, et al.
Publicado: (2015)

Effectiveness and Optical Quality of Topical 3.0% Diquafosol versus 0.05% Cyclosporine A in Dry Eye Patients following Cataract Surgery
por: Lee, Jang Hoon, et al.
Publicado: (2016)

Effects of Preservative-free 3% Diquafosol in Patients with Pre-existing Dry Eye Disease after Cataract Surgery: A Randomized Clinical Trial
por: Jun, Ikhyun, et al.
Publicado: (2019)

Tear film lipid layer increase after diquafosol instillation in dry eye patients with meibomian gland dysfunction: a randomized clinical study
por: Fukuoka, Shima, et al.
Publicado: (2019)

Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy
por: Godin, Morgan R, et al.
Publicado: (2017)

Effectiveness of hyaluronic acid and arnica extract ophthalmic solution in reducing dry eye symptoms in pediatric population
por: Buzzonetti, Luca, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qhph7h0v5jucgq5dhgste5rhms